NeurAxis (NRXS) Q1 2026 earnings review
The CPT Code Catalyst Finally Delivers
NeurAxis delivered a transformational quarter, proving its long-touted commercial thesis. The January 1 activation of the Category I CPT code for PENFS drove an immediate 80% surge in Q1 revenue to $1.6M, breaking the company out of its $800k-$900k historical quarterly range. Crucially, the quality of revenue is improving: shifting from discounted patient assistance programs to full-price insurance reimbursement expanded gross margins by 200 bps to 86.4%. Operating leverage is finally visible, with operating expenses nearly flat (+3%) against massive top-line growth, reducing operating loss by 24%. While hospital-level bottlenecks mean growth is currently concentrated among early adopters, the long-term commercial execution phase has successfully begun.
🐂 Bull Case
The new CPT code is successfully migrating patients away from 65%-discounted financial assistance programs, driving higher average selling prices and structurally higher gross margins.
Revenue grew 80%, but total operating expenses increased just 3%. If this dynamic holds, the path to cash flow breakeven becomes highly realistic.
🐻 Bear Case
Revenue growth is currently 'top-heavy,' relying heavily on a small cohort of children's hospitals that have aligned payer mix and dedicated clinic times. Broad scaling remains unproven.
Even with 100M+ covered lives, some hospitals hesitate to adopt IB-Stim broadly if regional coverage is low, fearing unequal care for non-covered patients.
⚖️ Verdict: 🟢
Bullish. The 80% revenue jump proves that the CPT code was a legitimate, structural catalyst, not just a management talking point. If the company can navigate hospital administrative hurdles and systematically expand payer coverage, the path to profitability is clear.
Key Themes
Category I CPT Code Drives Acceleration
Accelerating. The January 1, 2026 activation of the Category I CPT code was the primary growth engine, driving an 80% YoY revenue increase and a 35% jump in unit deliveries. This structural change provides a permanent billing solution and physician RVUs, incentivizing hospitals to shift from discounted programs to full-price orders. This single event completely changed the company's financial trajectory.
FDA Label Expansion and Clinical Validations
Stable. NeurAxis secured the first-ever FDA clearance for abdominal pain in functional dyspepsia (FD) and expanded its age range from 8-21 years to 8 years and older. Concurrently, the treatment duration was expanded from 3 to 4 devices per patient. This significantly increases the total addressable market while utilizing the exact same commercial sales infrastructure.
Veterans Affairs Penetration
Accelerating. The newly awarded Veterans Affairs Federal Supply Schedule (FSS) contract officially designates NeurAxis as a federal contractor. With early indications of unexpected Q1 orders, this provides immediate access to approximately 7 million VA patients, creating a secondary revenue stream outside the traditional pediatric hospital market.
Proprietary PENFS Technology Advantage
Stable. The company's IB-Stim device, utilizing proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS), remains the only FDA-cleared treatment recommended in academic society pediatrics guidelines for functional abdominal pain in IBS. This exclusivity forms the foundation for all payer coverage negotiations.
Hospital-Level Administrative Bottlenecks
Decelerating. Despite favorable codes and coverage, internal hospital bureaucracy remains a severe friction point. Securing dedicated weekly clinic time for IB-Stim requires multiple committee approvals. This extends the sales cycle and limits capacity even at highly willing hospitals.
Macro: Payer Coverage Gaps and 'Health Equity'
Stable. While the company touts 100M+ covered lives, the localized reality is different. Hospitals where only 25% of patients have insurance coverage for IB-Stim are blocking broad adoption due to 'health equity' concerns—refusing to offer a treatment that 75% of their demographic cannot afford. Wide national payer adoption is required to break this macroeconomic/industry logjam.
Adult Market Disconnect
Stable. There is a glaring contradiction in the narrative regarding the adult market. The company recently celebrated an FDA label expansion for patients '8 years and older.' However, broad insurance coverage for the adult TAM will not happen soon; it requires the completion of an 18-month randomized controlled trial (RCT) at the Cleveland Clinic. The immediate revenue impact of the adult FDA clearance is heavily blunted by this payer reality.
Other KPIs
Accelerating. Expanded by 200 basis points year-over-year (from 84.4%). This is direct evidence that the CPT code is successfully migrating patients off discounted financial assistance programs and onto full-price, high-margin reimbursement plans.
Stable. Total operating expenses increased by only 3% year-over-year. Selling expenses increased significantly (from $500k to $824k) to drive revenue, but this was offset by a reduction in G&A (from $2.43M to $2.20M), primarily due to the absence of a one-time legal settlement incurred in the prior year.
Stable. The balance was bolstered by an additional $2.1 million raised through an ATM facility and warrant exercises in April and May 2026. With operating losses reduced to $1.74M for the quarter, the company has adequate runway to execute its commercial ramp over the next 12-18 months.
Guidance
Accelerating. Management explicitly expects to achieve operating leverage throughout 2026. Selling and R&D expenses will rise to support commercialization and the adult clinical trial, but G&A is expected to remain flat or decrease. The 24% YoY improvement in operating loss in Q1 serves as early validation of this trend.
Key Questions
Hospital Onboarding Metrics
Given the 'top-heavy' nature of Q1 revenue, how many net new hospitals actively established dedicated IB-Stim clinic times this quarter compared to historical averages?
Health Equity Pushback
How is the commercial team pivoting its pitch to hospital administrators who cite 'health equity' concerns as a reason to block IB-Stim adoption?
Payer Coverage Milestones
With the CPT code now active, what is the specific target for expanding total covered lives beyond the current 100 million benchmark by year-end?
Cash Flow Breakeven Timeline
Assuming gross margins stabilize in the mid-to-high 80s and operating leverage continues, what annualized revenue run-rate is required to achieve cash flow breakeven?